AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7617857 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined hormonal replacement therapy (HRT)
Number of subjects: 41
Study 2213552 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac, 200 mg daily for 1 week
Number of subjects: 12
Study 2213552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 505369 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfinpyrazone
Number of subjects: 16
Study 30253440 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with hypermobility of the bladder neck
Number of subjects: 140
Study 30253440 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged >60 years with vaginal atrophy
Number of subjects: 140
Study 30253440 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal trophism assessed by pelvic examination
Number of subjects: 140
Study 30253440 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle strength across all groups
Number of subjects: 140
Study 27941424 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of oral tedizolid phosphate once daily for 10 days
Number of subjects: 100
Study 27941424 — intervention group
Group type: EXPERIMENTAL
Intervention: 200, 300, or 400 mg of oral tedizolid phosphate once daily for 21 days
Number of subjects: 100
Study 27941424 — intervention group
Group type: COMPARATOR
Intervention: 600 mg of oral linezolid twice daily for 21 days
Number of subjects: 100
Study 27941424 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo for 21 days
Number of subjects: 100
Study 25694201 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 302
Study 25694201 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety disorders
Number of subjects: 302
Study 25694201 — intervention group
Group type: EXPERIMENTAL
Intervention: African American race/ethnicity
Number of subjects: 302
Study 22469418 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural S-equol (10 mg S-equol daily for 12 weeks)
Number of subjects: 54
Study 22469418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 21897773 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular stimulation
Number of subjects: 198
Study 21897773 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 198
Study 20014253 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser treatment (635 nm, 17.5 mW, 3 times per week for 2 weeks)
Number of subjects: 67
Study 20014253 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control)
Number of subjects: 67
Study 20014253 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser treatment
Number of subjects: 67
Study 17023708 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 40% of energy as carbohydrate
Number of subjects: 57
Study 17023708 — intervention group
Group type: COMPARATOR
Intervention: Diet with 60% of energy as carbohydrate
Number of subjects: 57
Study 14583848 — intervention group
Group type: EXPERIMENTAL
Intervention: L-glutamine 30 g/day
Number of subjects: 25
Study 14583848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 11054630 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (0.5 mg/kg body weight, intracoronary)
Number of subjects: 30
Study 11054630 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous adenosine (20 mg intracoronary)
Number of subjects: 30
Study 11054630 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 30
Study 8686403 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 0
Study 8686403 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM association
Number of subjects: 0
Study 8686403 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with biochemical modulators
Number of subjects: 0
Study 1539810 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane at 1.0 MAC
Number of subjects: 73
Study 1539810 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 1.0 MAC
Number of subjects: 73
Study 1539810 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane at 1.5 MAC
Number of subjects: 73
Study 1539810 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 1.5 MAC
Number of subjects: 73
Study 1539810 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane at 1.0 MAC (Infants)
Number of subjects: 73
Study 1539810 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 1.0 MAC (Infants)
Number of subjects: 73
Study 2580158 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 118.587 (Corwin)
Number of subjects: 12
Study 2580158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31518440 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF+CTG+i-PRF (700 rpm for 3 min)
Number of subjects: 72
Study 31518440 — intervention group
Group type: COMPARATOR
Intervention: CAF+CTG
Number of subjects: 72
Study 31518440 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF+CTG+i-PRF
Number of subjects: 72
Study 28453868 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training (performed on the same day or on different days)
Number of subjects: 0
Study 28453868 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training (performed on alternating days)
Number of subjects: 0
Study 28453868 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained habitual physical activity)
Number of subjects: 0
Study 26636423 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 10
Study 26636423 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide + L-NMMA
Number of subjects: 10
Study 26636423 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 10
Study 24424074 — intervention group
Group type: EXPERIMENTAL
Intervention: Pistachios (P)
Number of subjects: 20
Study 24424074 — intervention group
Group type: COMPARATOR
Intervention: White bread (WB)
Number of subjects: 20
Study 24424074 — intervention group
Group type: COMPARATOR
Intervention: White bread + butter + cheese (WB+B+Ch)
Number of subjects: 20
Study 22348319 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-actuated nebulizer (BAN) delivering albuterol 2.5 mg or albuterol 2.5 mg plus ipratropium 0.25 mg
Number of subjects: 28
Study 22348319 — intervention group
Group type: COMPARATOR
Intervention: Standard nebulizer delivering albuterol 2.5 mg or albuterol plus ipratropium 0.5 mg
Number of subjects: 28
Study 20414852 — intervention group
Group type: EXPERIMENTAL
Intervention: Needs-Oriented Discharge Planning and Monitoring intervention, consisting of two sessions led by an intervention worker.
Number of subjects: 0
Study 18683666 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump surgery (CPB)
Number of subjects: 40
Study 18683666 — intervention group
Group type: COMPARATOR
Intervention: Off-pump surgery (no CPB)
Number of subjects: 40
Study 16168737 — intervention group
Group type: EXPERIMENTAL
Intervention: Left medial temporal-lobe lesion patients
Number of subjects: 28
Study 16168737 — intervention group
Group type: COMPARATOR
Intervention: Normal participants
Number of subjects: 28
Study 16168737 — intervention group
Group type: EXPERIMENTAL
Intervention: Right medial temporal-lobe lesion patients
Number of subjects: 28
Study 15270793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Number of subjects: 59
Study 11382623 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% once daily
Number of subjects: 596
Study 11382623 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% twice daily
Number of subjects: 596
Study 11382623 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily
Number of subjects: 596
Study 11382623 — intervention group
Group type: COMPARATOR
Intervention: Bimatoprost 0.03% once daily vs Timolol 0.5% twice daily
Number of subjects: 596
Study 9225576 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrografin (100 ml administered through nasogastric tube)
Number of subjects: 127
Study 9225576 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (control group)
Number of subjects: 127
Study 8355313 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with anti-pseudomonal third-generation cephalosporin (cefoperazone or ceftazidime)
Number of subjects: 109
Study 8355313 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy with anti-pseudomonal third-generation cephalosporin (cefoperazone or ceftazidime) plus gentamicin
Number of subjects: 109
Study 2834488 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (CY 222)
Number of subjects: 0
Study 2834488 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 0
Study 28991036 — intervention group
Group type: EXPERIMENTAL
Intervention: β-alanine (80 mg·kg body mass·d)
Number of subjects: 17
Study 28991036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 28991036 — intervention group
Group type: EXPERIMENTAL
Intervention: β-alanine
Number of subjects: 17
Study 25808719 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol condition (BAC = 0.08)
Number of subjects: 97
Study 25808719 — intervention group
Group type: EXPERIMENTAL
Intervention: High arousal condition
Number of subjects: 97
Study 25808719 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 97
Study 25808719 — intervention group
Group type: COMPARATOR
Intervention: Juice control group
Number of subjects: 97
Study 25808719 — intervention group
Group type: COMPARATOR
Intervention: Low arousal control condition
Number of subjects: 97
Study 25037676 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella 2.5
Number of subjects: 427
Study 25037676 — intervention group
Group type: COMPARATOR
Intervention: Intra-aortic balloon pump
Number of subjects: 427
Study 22884133 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stent technique
Number of subjects: 347
Study 22884133 — intervention group
Group type: COMPARATOR
Intervention: One-stent group
Number of subjects: 347
Study 22884133 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in < 60° group
Number of subjects: 347
Study 22884133 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in ≥ 60° group
Number of subjects: 347
Study 20698989 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT), treated 3 times per week for 12 weeks
Number of subjects: 51
Study 20698989 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 51
Study 18954481 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual inhibition task
Number of subjects: 0
Study 18954481 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor inhibition task
Number of subjects: 0
Study 18954481 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaction times analysis
Number of subjects: 0
Study 16647994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.2 mg/kg body weight)
Number of subjects: 46
Study 16647994 — intervention group
Group type: COMPARATOR
Intervention: Rectal diazepam (0.3 mg/kg body weight)
Number of subjects: 46
Study 12802027 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg/day for patients ≥13 years or ≥50 kg; 100 mg/day for patients <13 years or <50 kg)
Number of subjects: 39
Study 12802027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 10989404 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized reminder system
Number of subjects: 275
Study 10989404 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 275
Study 8781003 — intervention group
Group type: EXPERIMENTAL
Intervention: CQI-based intervention in 22 clinics receiving training, consultation, and networking
Number of subjects: 44
Study 8781003 — intervention group
Group type: COMPARATOR
Intervention: Matched comparison clinics (control group)
Number of subjects: 44
Study 1483156 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine injection (unconditioned stimulus) for three or four days
Number of subjects: 0
Study 1483156 — intervention group
Group type: COMPARATOR
Intervention: Conditioned stimulus (CS) followed by saline injection
Number of subjects: 0
Study 1483156 — intervention group
Group type: EXPERIMENTAL
Intervention: Utrecht group experimental design
Number of subjects: 0
Study 4018061 — intervention group
Group type: EXPERIMENTAL
Intervention: greater than LT (N = 11; trained at 69 watts above the workload associated with LT)
Number of subjects: 33
Study 4018061 — intervention group
Group type: EXPERIMENTAL
Intervention: = LT (N = 12; trained at the workload associated with LT)
Number of subjects: 33
Study 4018061 — intervention group
Group type: COMPARATOR
Intervention: C (N = 10)
Number of subjects: 33
Study 29478510 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) treatment
Number of subjects: 50
Study 29478510 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline S100B, Tau, UCH‐L1, IL‐1β, IL‐6, IL‐8, IL‐10, IL‐13, TNF‐α, IFN‐γ levels
Number of subjects: 50
Study 29478510 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Tau and day 5 BDNF levels
Number of subjects: 50
Study 27512886 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 40
Study 27512886 — intervention group
Group type: COMPARATOR
Intervention: Sham ESWT (Control)
Number of subjects: 40
Study 24342419 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-focus 12-step group (Double Trouble in Recovery; DTR)
Number of subjects: 203
Study 24342419 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 203
Study 22209649 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-control group (participants had a choice to use or not use a balance pole)
Number of subjects: 28
Study 22209649 — intervention group
Group type: COMPARATOR
Intervention: Yoked group (received the same balance pole on the schedule used by the self-control group)
Number of subjects: 28
Study 22209649 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-control group
Number of subjects: 28
Study 22209649 — intervention group
Group type: COMPARATOR
Intervention: Yoked group
Number of subjects: 28
Study 20483164 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 61
Study 18040883 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalent VFX
Number of subjects: 974
Study 18040883 — intervention group
Group type: COMPARATOR
Intervention: Incident VFX
Number of subjects: 974
Study 16187966 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 5239
Study 16187966 — intervention group
Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 5239
Study 16187966 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control and Rate control
Number of subjects: 5239
Study 12201397 — intervention group
Group type: EXPERIMENTAL
Intervention: GD2‐KLH/MPL‐A conjugate
Number of subjects: 7
Study 10364658 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (>/=120% of ideal body weight)
Number of subjects: 325
Study 10364658 — intervention group
Group type: COMPARATOR
Intervention: Non-obese patients (<120% of ideal body weight)
Number of subjects: 325
Study 10364658 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without vascular risk factors
Number of subjects: 325
Study 7573730 — intervention group
Group type: EXPERIMENTAL
Intervention: Short nasogastric tube (NGT)
Number of subjects: 55
Study 7573730 — intervention group
Group type: COMPARATOR
Intervention: Long nasointestinal tube (LT)
Number of subjects: 55
Study 2255262 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium pidolate (1 g elemental calcium)
Number of subjects: 20
Study 2255262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6997738 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis B vaccine
Number of subjects: 1083
Study 6997738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1083
Study 31279534 — intervention group
Group type: COMPARATOR
Intervention: Glycine augmentation of psychotropic drug treatment
Number of subjects: 2
Study 31279534 — intervention group
Group type: COMPARATOR
Intervention: D-cycloserine augmentation of psychotropic drug treatment
Number of subjects: 2
Study 28898687 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (200mg orally at enrollment, second dose after 24h if applicable)
Number of subjects: 149
Study 28898687 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 149
Study 28898687 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 149
Study 28898687 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone and Expectant management
Number of subjects: 149
Study 26498005 — intervention group
Group type: EXPERIMENTAL
Intervention: GV1001 telomerase peptide vaccination
Number of subjects: 33
Study 23713238 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Banxia Houpo Decoction (MBHD)
Number of subjects: 89
Study 23713238 — intervention group
Group type: COMPARATOR
Intervention: Domperidone
Number of subjects: 89
Study 23713238 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurostan
Number of subjects: 89
Study 23713238 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone + Neurostan
Number of subjects: 89
Study 20044757 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and milk supplementation (45 g milk powder containing 350 mg calcium + 600 mg calcium/day)
Number of subjects: 36
Study 20044757 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and milk supplementation
Number of subjects: 36
Study 20044757 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 36
Study 19832771 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 800 mg
Number of subjects: 252
Study 19832771 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 1200 mg
Number of subjects: 252
Study 19832771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 17575399 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program for stress reduction (single-session including guidelines for worker mental health promotion, basic education lecture, and active listening training)
Number of subjects: 46
Study 17575399 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program for stress reduction
Number of subjects: 46
Study 17575399 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education program)
Number of subjects: 46
Study 15126582 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 or 5 mg mifepristone daily for 120 days
Number of subjects: 16
Study 11795850 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with ALNA (2 g daily)
Number of subjects: 0
Study 11795850 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with FO (1 g EPA + DHA daily)
Number of subjects: 0
Study 11795850 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil (80:20 mix of palm and sunflowerseed oils)
Number of subjects: 0
Study 11026996 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sulfasalazine (group 1)
Number of subjects: 22
Study 11026996 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group 2)
Number of subjects: 22
Study 8892775 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin (alpha-blocker)
Number of subjects: 43
Study 8892775 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (beta-blocker)
Number of subjects: 43
Study 2070286 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (initial daily dose of 450 mg, titrated to a maximum of 900 mg per day)
Number of subjects: 40
Study 2070286 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone with the addition of a second antiarrhythmic drug
Number of subjects: 40
Study 2070286 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 40
Study 6342407 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthokeratology (OK) treatment group
Number of subjects: 80
Study 6342407 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional hard contact lenses)
Number of subjects: 80
Study 30831344 — intervention group
Group type: EXPERIMENTAL
Intervention: Minipally program (intervention group)
Number of subjects: 361
Study 30831344 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 361
Study 30302666 — intervention group
Group type: EXPERIMENTAL
Intervention: tPCNL
Number of subjects: 72
Study 30302666 — intervention group
Group type: COMPARATOR
Intervention: cPCNL
Number of subjects: 72
Study 28039705 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 60
Study 28039705 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha (IFN-α)
Number of subjects: 60
Study 25348257 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofilament non‐braided suture (Ethilon)
Number of subjects: 0
Study 25348257 — intervention group
Group type: COMPARATOR
Intervention: Multifilament braided suture (Mersilene tape)
Number of subjects: 0
Study 22818539 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscope cystoscopy
Number of subjects: 66
Study 22818539 — intervention group
Group type: COMPARATOR
Intervention: Traditional cystoscopy
Number of subjects: 66
Study 22818539 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study 20483041 — intervention group
Group type: EXPERIMENTAL
Intervention: AS patients
Number of subjects: 32
Study 20483041 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA verification
Number of subjects: 32
Study 20483041 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (HVs)
Number of subjects: 32
Study 18582259 — intervention group
Group type: EXPERIMENTAL
Intervention: ILMA-FOS
Number of subjects: 42
Study 18582259 — intervention group
Group type: COMPARATOR
Intervention: LMA-CTrach
Number of subjects: 42
Study 15982132 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical data of eye movement behavior during reading
Number of subjects: 0
Study 15982132 — intervention group
Group type: COMPARATOR
Intervention: Random perturbation of the text being read
Number of subjects: 0
Study 12570326 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguentum Lymphaticum (UL) applied topically for 12 weeks
Number of subjects: 33